Aflibercept (Eylea)

DRUG4 trials

Sponsors

Hadassah Medical Organization, Bayer, Ahmad Zeeshan Jamil, Everest Medicines (China) Co.,Ltd.

Conditions

CataractDiabetic Macular Edema (DME)Diabetic Retinopathy (DR)Intravitreal InjectionNeovascular Age Related Macular Degeneration(nAMD)Neovascular Age-related Macular DegenerationPhacoemulfisication+IOL ImplantationPreterm Infants

Phase 2

A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration

Not yet recruitingNCT07798375

Everest Medicines (China) Co.,Ltd.Neovascular Age Related Macular Degeneration(nAMD)

Start: 2026-09-01End: 2028-10-01Target: 244Updated: 2026-09-10

Phase 4

Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.

Hadassah Medical OrganizationNeovascular Age-related Macular Degeneration

Start: 2013-10-31End: 2016-04-30Target: 48Updated: 2016-01-13

Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery

Not yet recruitingNCT07301775

Ahmad Zeeshan JamilCataract, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) +2

Start: 2026-01-01End: 2026-09-30Target: 166Updated: 2025-12-24

Unknown Phase

An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

RecruitingNCT06315556

BayerPreterm Infants, Retinopathy of Prematurity

Start: 2024-03-05End: 2027-04-30Target: 200Updated: 2026-08-26